Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504942 | 0.83 | HTR2A (0.36) | HTR2AHTR2CALDH1A1PDE10AHASPIN | |
| SCHEMBL5672286 | 0.81 | CCR2 (0.37) | HTR2AHTR2CKDM4EMEN1ALDH1A1 | |
| SCHEMBL476619 | 0.78 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL476675 | 0.76 | LMNA (0.34) | HTR2AHTR2CKDM4EMEN1ALDH1A1 | |
| SCHEMBL22434876 | 0.74 | SIRT2 (0.37) | HTR2AHTR2CKDM4EMEN1KMT2A | |
| SCHEMBL3299836 | 0.74 | SMN1; SMN2 (0.37) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL20505256 | 0.73 | CYP1A2 (0.34) | ALDH1A1 | |
| SCHEMBL476682 | 0.72 | HASPIN (0.44) | HTR2AHTR2CKDM4EMEN1GAA | |
| SCHEMBL476706 | 0.69 | MCL1 (0.36) | HTR2AHTR2CMCL1 | |
| SCHEMBL2479489 | 0.67 | KDM4E (0.44) | KDM4EMEN1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138424-B2 | Indole derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| EP-1507758-B1 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | SANOFI AVENTIS (FR) | 2005-11-02 | — | — | EP | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| EP-1507758-A2 | INDOLE DERIVATIVES AND THEIR USE AS LIGANDS FOR CB2 RECEPTORS | Sanofi-Aventis (FR) | 2005-02-23 | — | — | EP | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| WO-2003097597-A2 | INDOLE DERIVATIVES AND THE USE THEREOF AS CB2 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2003-11-27 | — | — | WO | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | HTR2A 23/4885HTR2C 6/4885KDM4E 2393/4885 |
| US-20060089345-A1 | Indole derivatives, method for preparating same and pharmaceutical compositions containing same | CNR2, CNR1, IDO2 | HTR2A 22/4885HTR2C 17/4885KDM4E 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.